Tiffany Padgett
Family · North Augusta, SCNPI 1205452471
Payments from drug & device makers
Across 262 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$1K
- GSK$920
- Regeneron Healthcare Solutions, Inc.$474
- Novartis$368
- Optinose US, Inc.$332
- plus $1K from 18 others
What the payments were for
- Food & beverage$5,37196%
- Education$2204%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,211 |
| Sanofi | 38 | $1,147 |
| GSK | 56 | $920 |
| Regeneron Healthcare Solutions, Inc. | 15 | $474 |
| Novartis | 16 | $368 |
| Optinose US, Inc. | 17 | $332 |
| Amgen | 11 | $269 |
| Pfizer | 10 | $157 |
| Sanofi-aventis U.S. LLC | 1 | $98 |
| Kaleo, Inc. | 6 | $91 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Mylan Specialty L.p. | 4 | $78 |
| Azurity Pharmaceuticals, Inc. | 3 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $47 |
| Grifols USA, LLC | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Eyevance Pharmaceuticals LLC | 2 | $34 |
| Merck | 2 | $26 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| LEO Pharma Inc. | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| CSL Behring | 1 | $19 |
| AbbVie | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $14 |
How this compares
$5,591 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 16 | $62,677 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $13,424 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $13,270 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,300 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $7,903 |
| DuleraMometasone/Formoterol | 16 | $5,732 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,789 |
| Azelastine Hcl | 65 | $1,847 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $1,340 |
| Fluticasone Propionate | 49 | $720 |
| Montelukast Sodium | 63 | $548 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $364 |
| Famotidine | 39 | $362 |
| Levocetirizine Dihydrochloride | 11 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSymbicort, Breztri Aerosphere | $1,211 | $22,57053 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $920 | $18,21223 claims |
| MerckDulera | $26 | $5,73216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.
Other family in North Augusta
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Kara Cooper GilmerAnderson$127K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
- Mary WilliamsColumbia$67K
- Michelle StrongGreenville$55K
- Karen McKerihanSummerville$54K
- Doris ReidSimpsonville$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.